Replies to post #103262 on Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

One week RGBP chart shows uptrend
The trend is in!
The trend is our Friend!

Dr. David Koo’s Making RGBP Great Again!
https://docoh.com/patent/by/companyId/1589150

KOO’s owns 169+ million shares of RGBPP preferred shares or 169 million reasons to see that RGBP is successful.
https://www.marketscreener.com/business-leaders/David-Raymond-Koos-06H0YV-E/biography/

Big News and Advancements

$RGBP to our knowledge is the only Stem Cell company to make the advancements, get this far, successfully with NR2F6.

Regen has Big Name Partners such as Eli Lilly, the NIH, Weill Cornell Medical College (part of Cornell University), Pan Am Cancer Research & Treatment Center, and the Newest - Chem Div.

Hope you all understand we are dealing with a drug that will be designed to be internationally approved in:

EUROPE
USA
JAPAN

In the US alone it will cost around 70m to go through FDA trials.

70m x 3 = approx 210m in investments alone $RGBP pic.twitter.com/HfxniiAgZw

— Galfy (@GalfyStocks) November 12, 2021

https://www.marketwatch.com/investing/secfile/15347408

https://www.prnewswire.com/news-releases/regen-biopharma-inc-announces-signing-of-a-letter-of-intent-to-acquire-an-in-vitro-diagnostics-start-up-company-canary-oncoceutics-inc-which-is-developing-functional-cancer-tests-for-personalized-medicine-301427159.html

New Partners – NIH (NCATS) - Pan Am Cancer Research and Treatment Center - Eli Lily & Company –

Weill Cornell Medical College (Cornell University)

https://news.weill.cornell.edu/news/2022/01/lymphoma-cell-metabolism-may-provide-new-cancer-target